Reversal of Tamoxifen Resistance (Hormone Resistance) by Addition of Sirolimus (mTOR Inhibitor) in Metastatic Breast Cancer

被引：10
|
作者：
Bhattacharyya, G. S. [1 ]
Biswas, J. [2 ]
Singh, J. K. [3 ]
Singh, M. [4 ]
Govindbabu, K. [5 ]
Ranade, A. A. [6 ]
Malhotra, H. [7 ]
Parikh, P. M. [8 ]
Shahid, T. [9 ]
Basu, S. [9 ]
机构：
[1] Orchid Nursing Home AMRI, Med Oncol & Clin Hematol, Kolkata, India
[2] CNCI, Kolkata, India
[3] Mahavir Canc Sansthan, Patna, Bihar, India
[4] Mahavir Canc Sansthan, Med Oncol, Patna, Bihar, India
[5] ICON ARO, Med Oncol, Bangalore, Karnataka, India
[6] ICON ARO, Med Oncol, Pune, Maharashtra, India
[7] ICON ARO, Med Oncol, Jaipur, Rajasthan, India
[8] ICON ARO, Med Oncol, Bombay, Maharashtra, India
[9] AMRI, Radiat Oncol, Kolkata, India
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70115-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
16LBA
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [1] Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer
    Eskiler, Gamze Guney
    Cecener, Gulsah
    Dikmen, Gokhan
    Egeli, Unal
    Tunca, Berrin
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 120 : 73 - 88
  • [2] Reversion of Hormone Treatment Resistance with the Addition of an mTOR Inhibitor in Endometrial Stromal Sarcoma
    Martin-Liberal, J.
    Benson, C.
    Messiou, C.
    Fisher, C.
    Judson, I.
    [J]. CASE REPORTS IN MEDICINE, 2014, 2014
  • [3] Tamoxifen Resistance in Breast Cancer
    Chang, Minsun
    [J]. BIOMOLECULES & THERAPEUTICS, 2012, 20 (03) : 256 - 267
  • [4] Understanding Resistance to Tamoxifen in Hormone Receptor-Positive Breast Cancer
    Higgins, Michaela J.
    Stearns, Vered
    [J]. CLINICAL CHEMISTRY, 2009, 55 (08) : 1453 - 1455
  • [5] Reversal of acquired resistance to pazopanib in soft tissue sarcoma with addition of an mTOR inhibitor: A case report
    Katz, Daniela
    Zick, Aviad
    Cohen, Jonathan E.
    Sonnenblick, Amir
    Fridman, Evgeniya
    Shaham, Dorith
    Peretz, Tamar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Tamoxifen as inhibitor of multidrug resistance mechanism in lung and breast cancer tumours
    Bogush, T. A.
    Bogush, E. A.
    Kirsanov, V. J.
    Dudko, E. A.
    Tchemeris, G. Y.
    Davidov, M. I.
    [J]. EJC SUPPLEMENTS, 2008, 6 (07): : 84 - 84
  • [7] MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
    Bhin, Jinhyuk
    Yemelyanenko, Julia
    Chao, Xue
    Klarenbeek, Sjoerd
    Opdam, Mark
    Malka, Yuval
    Hoekman, Liesbeth
    Kruger, Dinja
    Bleijerveld, Onno
    Brambillasca, Chiara S.
    Sprengers, Justin
    Siteur, Bjorn
    Annunziato, Stefano
    van Haren, Matthijs J.
    Martin, Nathaniel I.
    van de Ven, Marieke
    Peters, Dennis
    Agami, Reuven
    Linn, Sabine C.
    Boven, Epie
    Altelaar, Maarten
    Jonkers, Jos
    Zingg, Daniel
    Wessels, Lodewyk F. A.
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 220 (11):
  • [8] TAMOXIFEN RESISTANCE IN BREAST-CANCER
    WIEBE, VJ
    OSBORNE, CK
    FUQUA, SAW
    DEGREGORIO, MW
    [J]. CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, 1993, 14 (03) : 173 - 188
  • [9] HORMONE RESISTANCE, INVASIVENESS, AND METASTATIC POTENTIAL IN BREAST-CANCER
    CLARKE, R
    THOMPSON, EW
    LEONESSA, F
    LIPPMAN, J
    MCGARVEY, M
    FRANDSEN, TL
    BRUNNER, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1993, 24 (03) : 227 - 239
  • [10] Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer
    Lee, Jin Sun
    Yost, Susan E.
    Li, Sierra Min
    Cui, Yujie
    Frankel, Paul H.
    Yuan, Yate-Ching
    Schmolze, Daniel
    Egelston, Colt A.
    Guo, Weihua
    Murga, Mireya
    Chang, Helen
    Bosserman, Linda
    Yuan, Yuan
    [J]. CANCERS, 2022, 14 (13)
12345